Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BG.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JF.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.572NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.397NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Q.3 (Alpha)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.523NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.116 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.38 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.595.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.340NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.437NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.452NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.400NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JN.1.25NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JN.2.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.16 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.46.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.336NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.1.9NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.317NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.397NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CH.1.1.11NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FJ.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BN.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
DV.3.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.14NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.80NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
GG.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.3.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CK.1.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.34NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
GD.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.37.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.77NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FD.4.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.51NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.16.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.52NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CH.1.1.27NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.65NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.75NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.21NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.18.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.24NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
GL.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.1.24NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.78NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EG.1.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.1.45NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used